Sponsor’s Guide to IRB Approval (Part V): How to Speed Up IRB Approvals 

Institutional review board (IRB) approval is a critical milestone in clinical research, but it can also become a source of avoidable delay when submissions are incomplete, feedback is handled inefficiently, or amendments are managed reactively. 

For sponsors, the challenge is getting through review while preserving study momentum, maintaining compliance, and keeping sites aligned. The review process is designed to protect participants and ensure ethical study conduct, and that rigor should not be compromised. 

However, many delays stem from preventable operational issues found during review rather than the review process itself, including inconsistent documents, unclear rationales, missing materials, fragmented internal communication, or repeated changes submitted without a broader amendment strategy. 

Sponsors looking to speed up IRB approval should focus on disciplined execution across the full study lifecycle, from strong initial submissions and active IRB review timeline management to well-planned IRB amendments and internal workflows. When these elements are supported by clear ownership and cross-functional coordination, sponsors are better positioned to reduce IRB approval delays and avoid unnecessary resubmission cycles. 

High-quality initial submissions remain the most effective way to speed up IRB approval. A well-prepared package reduces the likelihood of early clarification requests and preventable delays. 

Before submission, sponsors should evaluate whether each document supports the same study narrative. The protocol, informed consent form, recruitment materials, investigator brochure or device information, subject-facing materials, and supporting documentation should align on study purpose, procedures, risks, benefits, visit schedules, compensation, privacy protections, and participant expectations. 

Even small inconsistencies can slow review. For example, reviewers may need clarification or revisions when: 

• The protocol describes one visit schedule but the consent form describes another. 

• Recruitment language overstates benefits or uses terminology not supported by the protocol. 

• Study risks are described differently across documents. 

A structured pre-submission quality check can help sponsors confirm that protocol, consent, and supporting documents are aligned, complete, and clearly written before they reach the IRB. These checks should verify that: 

• Required documents are included and current. 

• Version dates and file names are accurate and consistent. 

• Consent language aligns with the protocol. 

• Study risks, procedures, and participant responsibilities are clearly described. 

• Recruitment and participant-facing materials are appropriate for the intended audience. 

• Any local or site-specific information is complete. 

• Submission forms accurately reflect the study design and related materials. 

Clarity is equally important. Reviewers should be able to understand what the study involves, what participants will experience, and how risks are being addressed without having to infer meaning from dense or inconsistent documentation. Sponsors can reduce IRB approval delays by writing submissions in a way that is complete, direct, and easy to navigate. 

This doesn’t mean oversimplifying complex research—it means removing ambiguity. A submission that clearly explains the study, anticipates reviewer questions, and presents materials in an organized way is more likely to move efficiently through the IRB review timeline. 

Once a submission is under review, sponsors who actively manage the IRB review timeline through prompt responses, consolidated revisions, and clear communication are less likely to trigger additional review cycles. Delays often occur when reviewer feedback is addressed in fragments, responses are incomplete, or changes create new inconsistencies across documents. 

When the IRB requests clarification or revisions, sponsors should resist the urge to respond too quickly with partial answers. A fast but incomplete response can trigger additional questions and extend the review process. Instead, sponsors should focus on providing thoughtful, comprehensive, well-organized responses that directly address each reviewer comment and prevent incremental delays that extend overall approval time. 

A strong response process includes: 

• Assigning ownership for each comment or requested change. 

• Consolidating feedback into a single response tracker. 

• Confirming whether changes affect multiple documents. 

• Revising all impacted materials at the same time. 

• Providing a clear explanation for each change. 

• Ensuring final documents are internally consistent before resubmission. 

This approach helps sponsors avoid IRB resubmission cycles caused by preventable gaps. For example, if a reviewer asks for clarification on a study procedure described in the consent form, the sponsor should also verify whether the same language appears in the protocol synopsis, recruitment materials, or participant instructions. Updating only one document may solve the immediate comment while creating misalignment elsewhere. 

Communication also plays a central role. Unclear ownership can stall timelines, while uncoordinated stakeholder edits can make responses inconsistent or duplicative. Sponsors should establish a clear internal pathway for routing IRB questions to the appropriate regulatory, clinical, legal, or operational stakeholders. 

The goal is to move quickly without sacrificing completeness, accuracy, or the context reviewers need to close the loop efficiently. The review process is more likely to move forward and preserve submission quality when handled this way. 

Planning and submitting IRB amendments without disrupting study momentum 

IRB amendments are a normal part of clinical research. Protocols evolve, recruitment strategies and patient populations shift, study materials change, sites are added, and operational needs emerge over time. However, amendments can disrupt study momentum when they are submitted reactively or without a clear strategy. 

Sponsors should account for IRB amendments early in the study planning process. While not every change can be predicted, many common amendment categories can be managed more efficiently with proactive planning. Common amendment categories include: 

• Updates to study documents. 

• Changes to recruitment materials. 

• Revisions to consent forms. 

• Protocol clarifications. 

• Site-specific changes. 

• Modifications that affect participant-facing information. 

When possible, sponsors should strategically group related changes into a single amendment rather than submitting multiple separate amendments in close succession. Repeated submissions can create unnecessary review interruptions, increase administrative burden, and complicate site implementation. Grouping changes can help streamline review, provided the approach does not delay urgent participant safety updates or time-sensitive compliance requirements. 

Sponsors should provide clear documentation, justification for changes, and impact assessments that explain what is changing, why the change is needed, and how the change affects participants, sites, and study conduct. Reviewers should not have to determine the rationale by comparing redlines or piecing together context from multiple documents. 

A well-prepared amendment submission typically includes: 

• A concise summary of changes. 

• A clear rationale for the amendment. 

• Identification of all affected documents. 

• Clean and tracked versions, when appropriate. 

• Participant impact, including whether the change affects burden, risk, or study conduct. 

• An explanation of whether re-consent is needed. 

• Site or enrollment implications, if applicable. 

Understanding the practical effect of each change is especially important. Some amendments may have minimal operational effect, while others may influence enrollment, participant burden, risk information, visit schedules, or site activation. Sponsors should make these implications clear so the IRB can evaluate the amendment efficiently. 

IRB amendments should also be coordinated with downstream implementation. Approval is only one step. Sponsors need to ensure sites understand when new documents may be used, whether previously enrolled participants are affected, and how updated materials should be deployed. With that coordination, approved amendments are easier to implement in ways that maintain enrollment and site activation timelines. 

Internal workflow strategies that accelerate IRB approval and amendment review 

Operational discipline is essential to accelerate the IRB approval process for both initial applications and IRB amendments. Even the strongest study documents can be delayed by unclear ownership, poor version control, or disconnected internal review workflows. 

Sponsors should begin by defining who owns the submission process. This includes responsibility for assembling materials, confirming document quality, coordinating stakeholder input, responding to IRB feedback, and tracking approval milestones. When ownership is ambiguous, deadlines slip and accountability diffuses. 

Version control is another critical component. IRB submissions and amendments often involve multiple documents, stakeholders, and review rounds. Without a controlled system for naming, dating, tracking, and approving versions, teams risk submitting outdated or conflicting materials. 

A disciplined version control process should make it easy to identify: 

• The current approved version of each document. 

• Documents currently under revision. 

• Changes made in response to IRB feedback. 

• Materials included in each submission or amendment. 

• Site-specific versions, where applicable. 

• Final approved documents ready for implementation. 

Cross-functional coordination is equally important. Regulatory, clinical operations, legal, medical writing, safety, privacy, and study teams may all have input into IRB-related materials. The challenge is ensuring their input is integrated efficiently rather than sequentially and inconsistently. 

Sponsors can reduce administrative friction by establishing standard workflows for submission review, comment resolution, amendment planning, and approval tracking. These workflows should clarify when each function is involved, what they are responsible for reviewing, and how conflicting feedback is resolved. 

For example, if legal and clinical teams review consent language separately without coordination, the final document may contain revisions that are accurate in isolation but inconsistent when combined. A structured review process helps ensure the final submission reflects one aligned position. 

Sponsors should also consider maintaining a forward-looking amendment log. This allows teams to capture potential changes as they arise, assess urgency, determine whether changes can be grouped, and plan submissions around enrollment or site activation milestones. Instead of treating IRB amendments as isolated events, sponsors can manage them as part of the broader study lifecycle. 

Speeding up IRB approval depends on disciplined execution throughout the study lifecycle, with strong initial submissions, active management of the IRB review timeline, and well-planned IRB amendments working together to reduce delays, avoid resubmission cycles, and support continued enrollment, site activation, and study conduct. 

Sponsors that invest in clear processes, cross-functional alignment, and submission quality are better positioned to accelerate IRB approval process milestones without compromising compliance. The result is a more predictable review experience and a stronger foundation for keeping clinical research moving forward. 

This is part five of a six part series on A Sponsor’s Guide to IRB Approval. Explore more in this series by clicking any of the links below.

• Sponsor’s Guide to IRB Approval (Part I): What Every Sponsor Needs to Know Before Submitting a Study 
• Sponsor’s Guide to IRB Approval (Part II): How to Draft a Clinical Trial Protocol That Stands Up to IRB Scrutiny 
• Sponsor’s Guide to IRB Approval (Part III): Building an IRB-Ready Informed Consent
• Sponsor’s Guide to IRB Approval (Part IV): Preparing IRB Documents That Prevent Delays
• Sponsor’s Guide to IRB Approval (Part V): How to Speed Up IRB Approvals